$IDA

The Bull Case For IDACORP (IDA) Could Change Following Stronger Profitability And Higher 2026 EPS Guidance

Simply Wall St discusses IDACORP (NYSE:IDA) Q2 2026 results, citing sales of $468.67 million and net income of $102.58 million, with higher EPS from continuing operations vs. 2025. It says IDACORP raised full-year 2026 diluted EPS guidance to $6.30 to $6.45. The piece links guidance to updated expectations for Idaho Power tax credit usage.

Original reporting
Published Aug 11, 2026, 7:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 7:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Bull Case For IDACORP (IDA) Could Change Following Stronger Profitability And Higher 2026 EPS Guidance — source image
Decision brief

The 30-second read

$IDABullishMed
01

Why it matters

The key actionable item is the raised 2026 diluted EPS guidance range, which can shift near-term valuation expectations, while the longer-term risk remains regulatory approval of costs and returns.

02

Market read

Traders should focus on whether the market treats the guidance lift as repeatable earnings power or as assumption-driven, regulator-dependent variability.

03

What to watch

Investors may be underweighting the article’s own emphasis that future returns depend on regulatory decisions on cost recovery and large capital project economics.

Relevance 7/10Novelty 6/10Timing: post Q2 results, ahead of next earnings/regulatory updates

Background

The piece frames IDACORP as a regulated electric utility where earnings stability and dividends depend on regulatory outcomes, including tax credit treatment.

Company-level read

Ticker impact

$IDABullishMedium confidence
Context

IDACORP reported Q2 2026 results and raised full-year 2026 diluted EPS guidance to $6.30 to $6.45 tied to updated tax credit usage expectations.

Expected impact

Bias modestly positive near term as traders reprice 2026 EPS expectations, with follow-through dependent on regulators’ treatment of tax credits and allowed recovery.

Evidence & confidence

The article provides specific Q2 profitability context and a concrete EPS guidance range change, but it is framed as narrative analysis rather than a full new disclosure beyond the guidance update.

Market effects

Reinforces that regulated utilities’ earnings can be sensitive to tax credit mechanics and regulator treatment of allowed recovery.

Limited to the Idaho Power-related tax credit assumption referenced in the guidance.

Low; utility-specific guidance with no stated cross-border linkage.

Counterpoint

The guidance increase may reflect accounting or assumption changes around tax credit usage rather than durable operating improvement, so upside could fade if regulatory outcomes differ.

Key entities

  • IDACORP

    US regulated electric utility; reported Q2 2026 results and raised full-year 2026 diluted EPS guidance to $6.30 to $6.45.

  • Idaho Power

    Referenced as the entity whose 2026 tax credit usage expectations underpin the guidance increase.

Related articles

$IDAMedAI 8/10

IDACORP Q2 Profit Rises, Lifts FY26 Earnings Guidance

IDACORP reported Q2 net income of $102.6 million, or $1.79 per share, up from $95.8 million, or $1.76 per share a year earlier, citing customer growth and higher rates. Retail revenues per MWh fell to $27.5 from $44.0. For FY2026, it raised the lower end of EPS guidance to $6.30-$6.45 from $6.25-$6.45.

$IDAMed

IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range

IDACORP INC (IDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 July 30, 2026 IDACORP, Inc. Announces Second Quarter 2026 Results, Increases Lower-End of Earnings Guidance Range BOISE, Idaho--IDACORP, Inc. (NYSE: IDA) reported second quarter 2026 net income attributable to IDACORP of $102.6 million, or $1.79 per diluted share, co

$LWHighAI 9/10

Lamb Weston Stock Jumps As Beat-And-Raise Ignites Turnaround Hopes

Lamb Weston Holdings Inc. (NYSE: LW) stock rose 4.15% after reporting Q1 FY27 revenue of $1.67B (up 1%) and adjusted EPS of $0.75 (beating estimates). The company raised its FY27 adjusted EPS guidance to $3.05–$3.35. Analysts reacted with mixed price target increases, citing strong North American performance but noting debt and EMEA challenges.

$LWHighAI 9/10

Lamb Weston Stock Jumps After Earnings Beat And Guidance Hike

Lamb Weston Holdings Inc. (NYSE: LW) stock rose 4.15% after reporting Q3 revenue of $1.67B and adjusted EPS of $0.75, beating estimates. The company raised FY27 guidance, with adjusted EPS now expected between $3.05 and $3.35. Analysts upgraded targets, with some setting a $58 price target. The stock has gained 20% in two weeks, driven by strong North American performance and cost savings.

$REGNMed

Regeneron reports sustained efficacy for FOP treatment Pasatru

Regeneron Pharmaceuticals reported 84-week trial data for Pasatru, showing sustained efficacy in treating fibrodysplasia ossificans progressiva. Compared to placebo, Pasatru had fewer new lesions and flare-ups. Common side effects included acne and epistaxis. The FDA approved Pasatru based on 56-week data, and a regulatory review is ongoing in Europe. Regeneron plans a Phase 3 trial in younger patients later this year.

$REGNMed

Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP

Regeneron (NASDAQ: REGN) reported 84-week data from the Phase 3 OPTIMA trial showing sustained efficacy of Pasatru in adults with FOP, reducing new HO lesions and flare-ups. The trial met its primary endpoint at 56 weeks, with continued benefits observed at 84 weeks. Pasatru was FDA-approved based on the 56-week trial results. The company plans to initiate a Phase 3 trial in adolescents and children with FOP later this year.